CSIMarket
 


Alaunos Therapeutics Inc   (TCRT)
Other Ticker:  
 

Alaunos Therapeutics Inc 's Working Capital Ratio

TCRT's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




TCRT Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 16.67 % 96.98 % 11.99 % -16.98 % 64.64 %
Y / Y Current Assets Change -42.51 % -31.37 % -38.1 % -49.16 % -44.25 %
Working Capital Ratio MRQ 1.69 2.29 3.29 4.91 3.43
Overall Ranking # # # # #
Seq. Current Liabilities Change 22.76 % 26.09 % 32.37 % -43.06 % 107.26 %
Seq. Current Assets Change -9.54 % -12.05 % -11.49 % -18.36 % 7.99 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 1.69 above Alaunos Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry Alaunos Therapeutics Inc booked the highest Working Capital Ratio than Alaunos Therapeutics Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is TCRT most successful ?
Working Capital Ratio TCRT on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Alaunos Therapeutics Inc 's Current Liabilities $ 33 Millions Visit TCRT's Balance sheet
Alaunos Therapeutics Inc 's Current Assets $ 56 Millions Visit TCRT's Balance sheet
Source of TCRT's Sales Visit TCRT's Sales by Geography


Cumulative Alaunos Therapeutics Inc 's Working Capital Ratio

TCRT's Working Capital Ratio for the trailling 12 Months

TCRT Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 16.67 % 96.98 % 11.99 % -16.98 % 64.64 %
Y / Y Current Assets TTM Growth -42.51 % -31.37 % -38.1 % -49.16 % -44.25 %
Working Capital Ratio TTM 2.74 3.32 4.23 4.92 5.67
Total Ranking TTM # 1442 # 1619 # 1349 # 1244 # 828
Seq. Current Liabilities TTM Growth 22.76 % 26.09 % 32.37 % -43.06 % 107.26 %
Seq. Current Assets TTM Growth -9.54 % -12.05 % -11.49 % -18.36 % 7.99 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to growth in Current Liabilities in the III. Quarter to $32.87 millions, average cumulative Working Capital Ratio decreased to 2.74 below the Alaunos Therapeutics Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 364 other companies have achieved higher Working Capital Ratio than Alaunos Therapeutics Inc . While Working Capital Ratio overall ranking has improved so far to 0, from total ranking in previous quarter at 1588.

Explain Working Capital Ratio
Where is TCRT most successful ?
Working Capital Ratio TCRT on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 365
Healthcare Sector # 692
Within the Market # 1441


TTM Working Capital Ratio Statistics
High Average Low
10.21 6.1 2.62
(Jun 30 2020)   (Sep 30 2018)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Nighthawk Biosciences inc   4.60 $ 66.474  Millions$ 14.451  Millions
Trevena inc   4.60 $ 42.540  Millions$ 9.257  Millions
Insmed Inc  4.59 $ 632.165  Millions$ 137.654  Millions
Acadia Pharmaceuticals Inc   4.48 $ 521.700  Millions$ 116.570  Millions
Revelation Biosciences Inc   4.45 $ 6.505  Millions$ 1.463  Millions
Durect Corp  4.44 $ 59.346  Millions$ 13.357  Millions
Vaccinex Inc   4.40 $ 8.025  Millions$ 1.824  Millions
2seventy Bio Inc   4.37 $ 349.417  Millions$ 79.897  Millions
Kiniksa Pharmaceuticals Ltd   4.28 $ 241.815  Millions$ 56.492  Millions
G1 Therapeutics Inc   4.24 $ 157.465  Millions$ 37.134  Millions
Prophase Labs Inc   4.21 $ 70.326  Millions$ 16.693  Millions
Mirum Pharmaceuticals Inc   4.19 $ 215.556  Millions$ 51.398  Millions
Axsome Therapeutics Inc   4.19 $ 252.383  Millions$ 60.283  Millions
Emergent Biosolutions Inc   4.17 $ 1,118.500  Millions$ 268.400  Millions
Y mabs Therapeutics inc   4.16 $ 133.244  Millions$ 32.015  Millions
Gt Biopharma Inc   4.15 $ 20.872  Millions$ 5.025  Millions
Travere Therapeutics Inc   4.08 $ 534.842  Millions$ 131.032  Millions
Beigene Ltd   4.07 $ 5,749.168  Millions$ 1,411.311  Millions
Pacira Biosciences inc   4.06 $ 533.411  Millions$ 131.526  Millions
Theriva Biologics inc   4.00 $ 52.731  Millions$ 13.192  Millions
Horizon Therapeutics Public Limited Company  3.96 $ 3,412.009  Millions$ 860.614  Millions
Galera Therapeutics Inc   3.86 $ 44.917  Millions$ 11.632  Millions
Corbus Pharmaceuticals Holdings Inc   3.86 $ 67.348  Millions$ 17.469  Millions
Vtv Therapeutics Inc   3.85 $ 28.783  Millions$ 7.467  Millions
Dynavax Technologies Corporation  3.82 $ 932.944  Millions$ 244.080  Millions
Ani Pharmaceuticals inc  3.79 $ 309.377  Millions$ 81.627  Millions
Endo International Plc  3.78 $ 2,054.162  Millions$ 543.053  Millions
Societal Cdmo Inc   3.78 $ 49.494  Millions$ 13.105  Millions
Karyopharm Therapeutics Inc   3.77 $ 222.677  Millions$ 58.991  Millions
Amphastar Pharmaceuticals Inc   3.76 $ 384.222  Millions$ 102.190  Millions

Date modified: 2022-11-16T22:21:07+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ENTA's Profile

Stock Price

ENTA's Financials

Business Description

Fundamentals

Charts & Quotes

ENTA's News

Suppliers

ENTA's Competitors

Customers & Markets

Economic Indicators

ENTA's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071